Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J9PT
|
|||
| Former ID |
DNCL003090
|
|||
| Drug Name |
BMS-820836
|
|||
| Synonyms |
Liafensine; BMS-820836; UNII-R34ID086Z6; 1198790-53-2; R34ID086Z6; Liafensine [USAN:INN]; Liafensine (USAN); BMS 820836; SCHEMBL1120067; CHEMBL2364614; DTXSID60152610; VCIBGDSRPUOBOG-QFIPXVFZSA-N; AKOS032946316; D10443; 6-[(4s)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine; (S)-6-(2-methyl-4-(naphthalen-2-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl)pyridazin-3-amine; (5)-6-(2-methyl-4-(naphthalen-2-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl)pyridazin-3-amine; 3-Pyridazinamine, 6-((4S)-1,2,3,4-tetrahydr
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Major depressive disorder [ICD-11: 6A70.3; ICD-10: F32.2] | Phase 2 | [1] | |
| Company |
Bristol-Myers Squibb
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H22N4
|
|||
| Canonical SMILES |
CN1CC(C2=C(C1)C=C(C=C2)C3=NN=C(C=C3)N)C4=CC5=CC=CC=C5C=C4
|
|||
| InChI |
1S/C24H22N4/c1-28-14-20-13-19(23-10-11-24(25)27-26-23)8-9-21(20)22(15-28)18-7-6-16-4-2-3-5-17(16)12-18/h2-13,22H,14-15H2,1H3,(H2,25,27)/t22-/m0/s1
|
|||
| InChIKey |
VCIBGDSRPUOBOG-QFIPXVFZSA-N
|
|||
| CAS Number |
CAS 1198790-53-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study. Psychopharmacology (Berl). 2014 Jun;231(11):2299-310. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.